Aurora Cannabis Reports Revenues Of $75.5 Million For Q3, Doesn’t Provide Net Loss Figure

Aurora Cannabis (TSX: ACB) (NYSE: ACB) reported third quarter earnings after the bell today, electing to only file select data in the news release before the scheduled conference call. The firm reported net revenues of $75.5 million for the quarter, while not publishing an earnings per share or net loss figure. Adjusted EBITDA for the quarter was reported as being -$50.9 million for the period.

Net revenue overall was recorded as being $78.4 million, before provisions of $2.9 million were taken into account. Cannabis revenue during the quarter was $69.6 million. Of those revenues, $41.5 million was associated with the recreational cannabis market, $27.0 million was in the medical market, while the international medical cannabis market netted $4.0 million in revenues for Aurora.

In terms of associated expenses to achieve these revenues, Aurora has claimed that it is on the path to a run-rate of $40 – $45 million per quarter for selling, general and administrative expenses, despite spending a total of $80.1 million during the quarter in this expense category. Further expenditure data has not as of yet been provided.

In terms of Aurora’s cash position, the company reported $230.2 million as of March 31, an increase from December’s figure of $156.3 million. That increase was primarily driven by the company raising $206.4 million through its at-the-market offering and $22.0 million debt, which was partially offset by burning through $154.5 million during the quarter – which, unbelievably, was a significant quarter over quarter improvement.

Lastly, Aurora produced 36,207 kilograms of cannabis during the quarter, while only selling 12,729 kilograms.

Full financials have yet to be release by the company.

Aurora Cannabis last traded at $9.20 on the TSX.


Information for this briefing was found via Sedar and Aurora Cannabis. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Teck Resources Q1 Earnings: Defying Copper Industry Weakness

Equinox Ups Its Offer For Calibre: Investors Said No!

First Quantum Q1 Earnings: Copper Major Still Bleeding Cash

Recommended

Cardiol Sees First Patient Enrolled Under Phase III MAVERIC Clinical Trial

Rua Gold Hits 13.3 g/t Gold, 8.1% Antimony Over 1.25 Metres At Auld Creek

Related News

Aurora Cannabis Caps Rocky Week With Insider Selling 57% of Position

Aurora Cannabis (TSX: ACB) (NYSE: ACB) has had a rough week, and for investors, the...

Friday, December 20, 2019, 10:25:15 PM

Aurora Cannabis Posts Declining Q4 2021 Revenues Of $54.8 Million, Net Loss

Aurora Cannabis (TSX: ACB) this afternoon reported its fourth quarter financial results. The firm reported...

Monday, September 27, 2021, 06:16:23 PM

Federal Wage Subsidies Granted to Publicly Traded Cannabis Companies Eclipses $100 Million

On June 1, 2021, total wage subsidies doled out to publicly traded cannabis companies from...

Wednesday, June 2, 2021, 02:30:00 PM

Aurora Cannabis Sees Share Price Slide as Early Debt Conversion Looms

Aurora Cannabis (TSX: ACB) (NYSE: ACB) has experienced a sell off in morning trading following...

Monday, November 18, 2019, 12:13:47 PM

Aurora Cannabis: Canaccord Anticipates Q2 Revenues Of $69.5 Million

On Thursday, February 11th, Aurora Cannabis (TSX: ACB) (NYSE: ACB) is scheduled to release their...

Tuesday, February 9, 2021, 04:01:00 PM